Atrys Health SL - Asset Resilience Ratio

Latest as of June 2026: 0.08%

Atrys Health SL (ATRY) has an Asset Resilience Ratio of 0.08% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ATRY current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€259.00K

≈ $302.80K USD Cash + Short-term Investments

Total Assets

€315.60 Million

≈ $368.97 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Atrys Health SL's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Atrys Health SL.

Liquid Assets Composition Over Time

This chart breaks down Atrys Health SL's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ATRY total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€259.00K	0.08%
Total Liquid Assets	€259.00K	0.08%

Asset Resilience Insights

Limited Liquidity: Atrys Health SL maintains only 0.08% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Atrys Health SL Industry Peers by Asset Resilience Ratio

Compare Atrys Health SL's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Atrys Health SL (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Atrys Health SL.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.95%	€4.69 Million ≈ $5.48 Million	€494.04 Million ≈ $577.59 Million	-0.58pp
2024-12-31	1.53%	€8.93 Million ≈ $10.43 Million	€584.19 Million ≈ $682.98 Million	+1.44pp
2023-12-31	0.09%	€554.00K ≈ $647.68K	€629.00 Million ≈ $735.37 Million	-0.16pp
2022-12-31	0.25%	€1.77 Million ≈ $2.07 Million	€705.28 Million ≈ $824.55 Million	-0.91pp
2021-12-31	1.16%	€6.57 Million ≈ $7.68 Million	€565.63 Million ≈ $661.28 Million	-8.86pp
2020-12-31	10.02%	€17.61 Million ≈ $20.59 Million	€175.78 Million ≈ $205.50 Million	+0.07pp
2019-12-31	9.95%	€8.76 Million ≈ $10.24 Million	€88.04 Million ≈ $102.93 Million	-8.51pp
2018-12-31	18.46%	€9.91 Million ≈ $11.59 Million	€53.69 Million ≈ $62.77 Million	+18.11pp
2017-12-31	0.35%	€141.87K ≈ $165.86K	€40.20 Million ≈ $46.99 Million	-0.23pp
2016-12-31	0.59%	€179.05K ≈ $209.33K	€30.57 Million ≈ $35.74 Million	+0.39pp
2015-12-31	0.19%	€50.21K ≈ $58.70K	€26.10 Million ≈ $30.51 Million	-0.06pp
2014-12-31	0.26%	€50.21K ≈ $58.70K	€19.53 Million ≈ $22.83 Million	-1.37pp
2013-12-31	1.63%	€307.64K ≈ $359.67K	€18.87 Million ≈ $22.06 Million	-13.65pp
2012-12-31	15.28%	€2.80 Million ≈ $3.27 Million	€18.29 Million ≈ $21.39 Million	--

pp = percentage points

About Atrys Health SL

MC:ATRY Spain Biotechnology

Market Cap

$252.92 Million

€216.34 Million EUR

Market Cap Rank

#16576 Global

#109 in Spain

Share Price

€2.85

Change (1 day)

+0.18%

52-Week Range

€2.34 - €3.51

All Time High

€11.20